Exhibit 99.1 bioAffinity Technologies Reports First Quarter 2025 Results CyPathLung sales up 276% year-over-year SAN ANTONIO, Texas (May 15, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for accurate, noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the three months ended March 31, 2025. Key Highlights Management Commentary "We began 2025 with strong momentum, delivering 27 ...